Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 3, 2001
"Until a cure is found, Pennsylvania will continue to assist people who otherwise might be unable to get the medications they need to survive," Secretary Houstoun said. "Viread will potentially lower the chance of HIV- related infections and/or death for many people who are living with HIV."
With today's announcement, the SPBP now covers 68 types of drugs and treatments used to treat persons living with HIV/AIDS. The program currently serves almost 5,000 people statewide.
Pharmaceutical manufacturers created Viread to be used in combination with other anti-retroviral agents for the treatment of patients with HIV. Viread helps patients lower the amount of HIV in their blood and gain "T" cells, which are vital to stopping acquired immune deficiency syndrome (AIDS).
The SPBP, which began in 1987, is part of Pennsylvania's commitment to helping those living with HIV and AIDS to maintain the best quality of life possible; to help pay for expensive medications so they can remain in their homes and communities; and to avoid having to rely on further public assistance, if possible. The state also pays for HIV/AIDS drugs for individuals eligible for Medicaid.
In addition to paying for HIV/AIDS drugs, the SPBP also pays for Clozaril and four other anti-psychotic medications that are used to control schizophrenia.
After the FDA approves a drug for the treatment of HIV/AIDS, the Department of Public Welfare conducts a comprehensive review before adding a drug to its approved medications. This ensures the financial viability of the program and continuation of services to persons already in the program without creating barriers such as waiting lists or formulary deletions.
To be eligible, individuals must reside in Pennsylvania, but not in an institution; have an individual gross income of less than $30,000 with an additional allowance of $2,480 for each additional family member; and have a medical need for the drug.
Applications are available from county assistance offices, AIDS service agencies, hospital social service departments, state health centers, hemophilia and renal dialysis centers, mental health centers, and some physicians and pharmacies.
For more information about the SPBP or an application, call toll-free at 1-800-922-9384; write to the Department of Public Welfare, Special Pharmaceutical Benefits Program, P.O. Box 8021, Harrisburg, PA 17105; or visit DPW through the PA PowerPort at http://www.state.pa.us or directly at http://www.dpw.state.pa.us.
CONTACT: Jay Pagni or Stephanie Suran, +1-717-787-4592, both of the Pennsylvania Department of Public Welfare.
SOURCE Pennsylvania Department of Public Welfare
Web Site: http://www.dpw.state.pa.us
011203
PR011203
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .